Gam-COVID-Vac

Phase 3Biologic

GGamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation

Gam-COVID-Vac is one of 64 biologic programs targeting Severe Acute Respiratory Syndrome. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Severe Acute Respiratory SyndromeActive, not recruiting

COVID-19Active, not recruiting

Severe Acute Respiratory SyndromePhase 2/Phase 3

Active, not recruiting

COVID-19Phase 3

Active, not recruiting

Competition

Competitive Landscape

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

Gam-COVID-Vac

GGamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation

Phase 3

8 2

COVID-19 Vaccine

Moderna

Preclinical

27 3

Stivarga

Bayer

Preclinical

1 4

Aimovig

Amgen

Preclinical

1 5

Aldactone

Pfizer

Preclinical

1 6

Nexavar

Bayer

Preclinical

1 7

Activella

Eli Lilly

Preclinical

—8

Aquasol E

NNational Eye Institute (NEI)

Preclinical

1 9

Benadryl

PParkedale

Preclinical

1 10

SARS-COV-2 VACCINE

Moderna

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Recruiting

COVID-19

NCT04834869

Clinical

Trials by Indication[1]

COVID-198 trials

Clinical Trial of Efficacy, Safety, and Immunogenicity of Gam-COVID-Vac Vaccine Against COVID-19 in Belarus

Unknown status·GGamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation·Phase 3·NCT04564716·100 enrolled

COVID-19 Vaccines Safety Tracking (CoVaST)

Recruiting·MMasaryk University··NCT04834869·30,000 enrolled

An Open Study of the Safety, Tolerability and Immunogenicity of "Gam-COVID-Vac Lyo" Vaccine Against COVID-19

Completed·GGamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation·Phase 1/2·NCT04437875·38 enrolled

Show 5 more trials

Clinical Trial of the Immunogenicity, Safety, and Efficacy of the Gam-COVID-Vac Vaccine Against COVID-19 in Venezuela

Unknown status·GGamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation·Phase 3·NCT04642339·2,000 enrolled

Clinical Trial of Efficacy, Safety, and Immunogenicity of Gam-COVID-Vac Vaccine Against COVID-19

Unknown status·GGamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation·Phase 3·NCT04530396·33,758 enrolled

The Study of "Gam-COVID-Vac" Vaccine Against COVID-19 With the Participation of Volunteers of 60 y.o and Older

Unknown status·GGamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation·Phase 2·NCT04587219·110 enrolled

An Open Study of the Safety, Tolerability and Immunogenicity of the Drug "Gam-COVID-Vac" Vaccine Against COVID-19

Completed·GGamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation·Phase 1/2·NCT04436471·38 enrolled

A Phase III Clinical Trial of the Immunogenicity and Safety of the Gam-COVID-Vac Vaccine Against COVID-19 in the UAE

Unknown status·GGamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation·Phase 3·NCT04656613·1,000 enrolled

Severe Acute Respiratory Syndrome1 trial

Clinical Trial to Assess Safety and Immunogenicity of Gam-COVID-Vac Combined Vector Vaccine for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-Сov-2) Infection

Unknown status·—·Phase 2/3·NCT04640233·1,600 enrolled

Adolescent1 trial

Study of Gam-COVID-Vac in Adolescents

Unknown status·GGamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation·Phase 2/3·NCT04954092·3,000 enrolled

Immunogenicity1 trial

Safety, Tolerability and Immunogenicity of Gam-COVID-Vac Vaccine in a Nasal Spray

Unknown status·GGamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation·Phase 1/2·NCT05248373·400 enrolled

Sources

References

[1]
ClinicalTrials.gov — 11 trial records for Gam-COVID-Vac. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Gam-COVID-Vac compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Gam-COVID-Vac. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 3[1]
Company: GGamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation

Gam-COVID-Vac

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

COVID-198 trials

Severe Acute Respiratory Syndrome1 trial

Adolescent1 trial

Immunogenicity1 trial

References

Drug Info

Quick Facts

Related News